Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

02 Jun 2023

Posting of Annual Report and Notice of AGM

Investors
01 Jun 2023

Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group

Diagnostics | Investors
27 Apr 2023

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
24 Apr 2023

Preliminary Results for the year ended 31 December 2022

Investors
17 Apr 2023

Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting

Investors | Therapeutics
06 Apr 2023

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
05 Apr 2023

First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

Investors | Therapeutics
03 Apr 2023

Notice of Results and Investor Presentation

Investors
27 Mar 2023

Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting

Investors | Therapeutics
08 Mar 2023

Interview with Victoria Statham, VP Intellectual Property & Legal, Therapeutics

Blogs

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok